Where do we stand with immune checkpoint blockade for advanced cutaneous squamous cell carcinoma? A systematic review and critical appraisal of existing evidence
Steeb T, Wessely A, Heppt F, Harlaß M, Berking C, Heppt M (2020)
Publication Type: Journal article
Publication year: 2020
Journal
DOI: 10.1111/bjd.18957
Abstract
Immune checkpoint blockade (ICB) has tremendously changed the field of oncological therapy. Recently, the PD-1-blocking antibody cemiplimab was approved by the FDA and the EMA for the treatment of advanced cutaneous squamous cell carcinoma (cSCC).1 However, clinical practice guidelines currently do not cover specific recommendations regarding the management of advanced cSCC with ICB. Hence, we have performed a systematic review on the current use of ICB for advanced cSCC.
Authors with CRIS profile
Franz Heppt
Department of Dermatology
Carola Berking
Lehrstuhl für Haut- und Geschlechtskrankheiten
Markus Heppt
Department of Dermatology
Involved external institutions
Netherlands (NL)How to cite
APA:
Steeb, T., Wessely, A., Heppt, F., Harlaß, M., Berking, C., & Heppt, M. (2020). Where do we stand with immune checkpoint blockade for advanced cutaneous squamous cell carcinoma? A systematic review and critical appraisal of existing evidence. British Journal of Dermatology. https://doi.org/10.1111/bjd.18957
MLA:
Steeb, Theresa, et al. "Where do we stand with immune checkpoint blockade for advanced cutaneous squamous cell carcinoma? A systematic review and critical appraisal of existing evidence." British Journal of Dermatology (2020).
BibTeX: Download